Compass Pathways' stock rose 4% following new 52-week data from its Phase III study of COMP360, an oral psilocybin treatment for treatment-resistant depression (TRD). The data showed sustained symptom improvement with infrequent dosing, supporting the drug's safety and efficacy. Analysts at Jefferies are confident in FDA approval, noting the drug's Breakthrough Therapy Designation and priority review status, with a potential launch in early 2027. COMP360's less frequent dosing offers a competitive advantage over existing treatments like Johnson & Johnson's Spravato, with estimated peak sales of $1.5 billion and a company valuation between $3 billion and $4.5 billion.
Hayati®, a UK-based technology and vaping brand, partnered with elrow at the Edinburgh Festival to launch the "TURN UP WITH HAYATI®" activation. This collaboration featured a dedicated space with interactive activities, special festival edition produ...
FREELANDER participated in the 2026 Chery International User Summit in Wuhu, China, showcasing the international variant of its FREELANDER 8 model through a day-and-night program on October 19. The day featured the first international test drive on c...
Bitcoin (BTC) climbed 0.89% to surpass $82,000, with Ether (ETH) also gaining 0.45% near $2,400. The crypto market showed mixed performance: Monero (XMR) and Zcash (ZEC) rose over 2%, while sectors like Layer 1 and CeFi advanced modestly. However, so...
The Bitwise NEAR ETF (NRR) held 16.5 million NEAR tokens valued at over $82 million as of mid-October, with all assets staked to earn rewards. The fund reported a 3.31% net staking reward rate on Oct. 16, lower than the 4.94% gross rate, due to fees ...
South32 Ltd began fiscal year 2027 with an 11% rise in copper production at its Sierra Gorda mine, driven by higher ore grades and ongoing expansion efforts including a new grinding line to increase capacity by 25%. The company also saw a 14% increas...
